K.N. Chi

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer”.

Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

Annals of Oncology(2025)10.1016/j.annonc.2025.07.003

N/A

0.663DataRank · unranked

31 citations

K.N. Chi, Neal D. Shore, Ken Herrmann, Johann S. De Bono, Daniel Castellano +88 more

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study

UNC Libraries(2022)10.17615/wdx5-cx34

N/A

0DataRank · unranked

2 citations

A.S. Merseburger, D. Cella, S. Chowdhury, E. Basch, B. Miladinovic +16 more